Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States

References

• Ong SL, Garcea G, Pollard CA, et al. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology 2009;9:583-600
   PubMedGoogle Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Briefing Document: Oncology Drug Advisory Committee Meeting for Sutent (suntinib malate). United States Food and Drug Administration, Silver Spring, MD 2011
   Google Scholar
• Signorovitch J, Swallow E, Kantor E, et al. Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison of randomized trials. J Clin Oncol 2012;30(4 [February 1 Supplement]):abstr 237
   Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28:935-45
   PubMed Web of Science ®Google Scholar
• Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Medicine 1990;9:1259-76
   PubMed Web of Science ®Google Scholar
• Glasziou PP, Cole BF, Gelber RD, et al. Quality adjusted survival analysis with repeated quality of life measures. Stat Medicine 1998;17:1215-29
   PubMed Web of Science ®Google Scholar
• Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials 2003;24:682-701
   PubMedGoogle Scholar
• Briggs A, Claxton K, Sculpher M. Further developments in decision analytic models for economic evaluation. Decision modelling for health economic evaluation. New York: Oxford Univresity Press Inc., 2006. p 45-76
   Google Scholar
• Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-184, iii–iv
   PubMed Web of Science ®Google Scholar
• Wojcik M, McComas J, Sachs C, et al. A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET): Clinical Study Report [Data on file]. Novartis, 2010
   Google Scholar
• Casciano R, Chulikavit M, Parikh R, et al. Resource utilization among neuroendocrine tumor patients in the United States. J Clin Oncol 2012;30(4 [February 1 Supplement]):abstr 251
   Google Scholar
• RED BOOK™ for Windows® [database on CD-ROM]. Annual 2011 Edition. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc.
   Google Scholar
• Physicians’ Fee and Coding Guide 2011. MAG Mutual Healthcare Solutions, Inc, Atlanta, GA 2011
   Google Scholar
• Thomson Reuters. MS-DRG Handbook 2010. Comparative clinical and financial benchmarks. Thomson Reuters, Ann Arbor, MI.
   Google Scholar
• Healthcare Cost & Utilization Project (HCUP). Agency for Healthcare Research and Quality 2009. http://www.ahrq.gov/data/hcup/. Accessed May/June, 2011
   Google Scholar
• Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-6
   PubMed Web of Science ®Google Scholar
• Weiner M, Ross S, Mathew J, et al. Estimating the costs of chemotherapy-associated adverse event clusters. Health Serv Outcomes Res Method 2007;7:1-21
   Google Scholar
• Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-2169
   PubMed Web of Science ®Google Scholar
• Zhang B, Wright AA, Nilsson ME, et al. Associations between advanced cancer patients' end-of-life conversations and cost experiences in the final week of life. J Clin Oncol 2008;26(15 [May 20 Supplement]):abstr 9530
   Google Scholar
• Swinburn P, Lloyd A. Neuroendocrine Tumours (NET) Utility Values. 2011. [Data on file at Novartis].
   Google Scholar
• The AMCP format for formulary submissions: version 3.0. Academy of Managed Care Pharmacy, Alexandria, VA 2009
   Google Scholar
• Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64
   PubMed Web of Science ®Google Scholar
• Rawlins M, Culyer A. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Remák E, Charbonneau C, Négrier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26:3995-4000
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-42
   PubMed Web of Science ®Google Scholar
• Murphy K, Topel R. The value of health and longevity. J Pol Econ 2006;114:871-903
   Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Making decision models probabilistic. Decision modelling for health economic evaluation. New York: Oxford University Press Inc., 2006. p 77-120
   Google Scholar